Literature DB >> 15858010

Epitope-mapping studies define two major neutralization sites on the vaccinia virus extracellular enveloped virus glycoprotein B5R.

Lydia Aldaz-Carroll1, J Charles Whitbeck, Manuel Ponce de Leon, Huan Lou, Lauren Hirao, Stuart N Isaacs, Bernard Moss, Roselyn J Eisenberg, Gary H Cohen.   

Abstract

Vaccinia extracellular enveloped virus (EEV) is critical for cell-to-cell and long-range virus spread both in vitro and in vivo. The B5R gene encodes an EEV-specific type I membrane protein that is essential for efficient EEV formation. The majority of the B5R ectodomain consists of four domains with homology to short consensus repeat domains followed by a stalk. Previous studies have shown that polyclonal antibodies raised against the B5R ectodomain inhibit EEV infection. In this study, our goal was to elucidate the antigenic structure of B5R and relate this to its function. To do this, we produced multimilligram quantities of vaccinia virus B5R as a soluble protein [B5R(275t)] using a baculovirus expression system. We then selected and characterized a panel of 26 monoclonal antibodies (MAbs) that recognize B5R(275t). Five of these MAbs neutralized EEV and inhibited comet formation. Two other MAbs were able only to neutralize EEV, while five others were able only to inhibit comet formation. This suggests that the EEV neutralization and comet inhibition assays measure different viral functions and that at least two different antigenic sites on B5R are important for these activities. We further characterized the MAbs and the antigenic structure of B5R(275t) by peptide mapping and by reciprocal MAb blocking studies using biosensor analysis. The epitopes recognized by neutralizing MAbs were localized to SCR1-SCR2 and/or the stalk of B5R(275t). Furthermore, the peptide and blocking data support the concept that SCR1 and the stalk may be in juxtaposition and may be part of the same functional domain.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15858010      PMCID: PMC1091701          DOI: 10.1128/JVI.79.10.6260-6271.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  38 in total

Review 1.  The formation and function of extracellular enveloped vaccinia virus.

Authors:  Geoffrey L Smith; Alain Vanderplasschen; Mansun Law
Journal:  J Gen Virol       Date:  2002-12       Impact factor: 3.891

Review 2.  Multipin peptide libraries for antibody and receptor epitope screening and characterization.

Authors:  Gordon Tribbick
Journal:  J Immunol Methods       Date:  2002-09-01       Impact factor: 2.303

3.  Mapping CD55 function. The structure of two pathogen-binding domains at 1.7 A.

Authors:  Pamela Williams; Yasmin Chaudhry; Ian G Goodfellow; Jason Billington; Robert Powell; O Brad Spiller; David J Evans; Susan Lea
Journal:  J Biol Chem       Date:  2002-12-22       Impact factor: 5.157

4.  Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.

Authors:  Edward Bell; Mohammad Shamim; J Charles Whitbeck; Georgia Sfyroera; John D Lambris; Stuart N Isaacs
Journal:  Virology       Date:  2004-08-01       Impact factor: 3.616

5.  An antigenic difference between intracellular and extracellular rabbitpox virus.

Authors:  G Appleyard; A J Hapel; E A Boulter
Journal:  J Gen Virol       Date:  1971-10       Impact factor: 3.891

6.  A mutational analysis of the vaccinia virus B5R protein.

Authors:  Elizabeth C Mathew; Christopher M Sanderson; Ruth Hollinshead; Geoffrey L Smith
Journal:  J Gen Virol       Date:  2001-05       Impact factor: 3.891

Review 7.  Solution structures of complement components by X-ray and neutron scattering and analytical ultracentrifugation.

Authors:  S J Perkins; H E Gilbert; M Aslam; J Hannan; V M Holers; T H Goodship
Journal:  Biochem Soc Trans       Date:  2002-11       Impact factor: 5.407

8.  Human immunodeficiency virus type 1-neutralizing monoclonal antibody 2F5 is multispecific for sequences flanking the DKW core epitope.

Authors:  Alfredo Menendez; Keith C Chow; Oscar C C Pan; Jamie K Scott
Journal:  J Mol Biol       Date:  2004-04-23       Impact factor: 5.469

9.  Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions.

Authors:  Christiana Fogg; Shlomo Lustig; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen; Bernard Moss
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

10.  SRC mediates a switch from microtubule- to actin-based motility of vaccinia virus.

Authors:  Timothy P Newsome; Niki Scaplehorn; Michael Way
Journal:  Science       Date:  2004-08-05       Impact factor: 47.728

View more
  47 in total

1.  Antigenic and mutational analyses of herpes simplex virus glycoprotein B reveal four functional regions.

Authors:  Florent C Bender; Minu Samanta; Ekaterina E Heldwein; Manuel Ponce de Leon; Elina Bilman; Huan Lou; J Charles Whitbeck; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2007-01-31       Impact factor: 5.103

2.  Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Authors:  Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-25       Impact factor: 11.205

3.  Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.

Authors:  Aklile Berhanu; Rebecca L Wilson; Dana L Kirkwood-Watts; David S King; Travis K Warren; Susan A Lund; Lindsay L Brown; Alex K Krupkin; Erin Vandermay; Will Weimers; Kady M Honeychurch; Douglas W Grosenbach; Kevin F Jones; Dennis E Hruby
Journal:  J Virol       Date:  2008-01-16       Impact factor: 5.103

4.  Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

Authors:  Brice Barefoot; Natalie J Thornburg; Daniel H Barouch; Jae-Sung Yu; Christopher Sample; Robert E Johnston; Hua Xin Liao; Thomas B Kepler; Barton F Haynes; Elizabeth Ramsburg
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

5.  Surface Plasmon Resonance Reveals Direct Binding of Herpes Simplex Virus Glycoproteins gH/gL to gD and Locates a gH/gL Binding Site on gD.

Authors:  Tina M Cairns; Noah T Ditto; Doina Atanasiu; Huan Lou; Benjamin D Brooks; Wan Ting Saw; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2019-07-17       Impact factor: 5.103

6.  Antibody responses to vaccinia membrane proteins after smallpox vaccination.

Authors:  Steven J Lawrence; Kathleen R Lottenbach; Frances K Newman; R Mark L Buller; Clifford J Bellone; John J Chen; Gary H Cohen; Roselyn J Eisenberg; Robert B Belshe; Samuel L Stanley; Sharon E Frey
Journal:  J Infect Dis       Date:  2007-06-04       Impact factor: 5.226

7.  The heterogeneity of human antibody responses to vaccinia virus revealed through use of focused protein arrays.

Authors:  Jonathan S Duke-Cohan; Kristin Wollenick; Elizabeth A Witten; Michael S Seaman; Lindsey R Baden; Raphael Dolin; Ellis L Reinherz
Journal:  Vaccine       Date:  2009-01-13       Impact factor: 3.641

8.  Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.

Authors:  Cassandra L Braxton; Shelby H Puckett; Steven B Mizel; Douglas S Lyles
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

9.  Comparative evaluation of the immune responses and protection engendered by LC16m8 and Dryvax smallpox vaccines in a mouse model.

Authors:  Clement A Meseda; Anne E Mayer; Arunima Kumar; Alonzo D Garcia; Joseph Campbell; Paul Listrani; Jody Manischewitz; Lisa R King; Hana Golding; Michael Merchlinsky; Jerry P Weir
Journal:  Clin Vaccine Immunol       Date:  2009-07-15

10.  Molecular smallpox vaccine delivered by alphavirus replicons elicits protective immunity in mice and non-human primates.

Authors:  Jay W Hooper; Anthony M Ferro; Joseph W Golden; Peter Silvera; Jeanne Dudek; Kim Alterson; Max Custer; Bryan Rivers; John Morris; Gary Owens; Jonathan F Smith; Kurt I Kamrud
Journal:  Vaccine       Date:  2009-10-13       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.